Oral propranolol and retinopathy of prematurity

The efficacy of oral Propranolol in the treatment of the retinopathy of prematurity

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100512003915N21

Enrollment

Registered

2018-11-12

Start date

2018-04-23

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of prematurity. Retinopathy of prematurity

Interventions

Intervention 1: Intervention group: We start treatment with oral propranolol ( Osve, Iran) 0.5 mg/kg every 8 hr after detection of retinopathy of prematurity in first eye examination. Drug administrat

Eligibility

Sex/Gender

All

Age

28 Days to 120 Days

Inclusion criteria

Inclusion criteria: Preterm infants with gestational age of less than 30 weeks Birth weight less than 1250 grams Stage 1 or 2 for retinopathy of prematurity

Exclusion criteria

Exclusion criteria: Infants with congenital anomalies Congenital or acquired cardiovascular disease in neonate Acute renal failure Severe intra-ventricular hemorrhage

Design outcomes

Primary

Measure	Time frame
The need to intervention (laser therapy or Avastin administration) in retinopathy of prematurity. Timepoint: Corrected gestational age 38 weeks (gestational age plus age after birth in weeks). Method of measurement: Ophthalmoscopic eye examination and performing laser therapy or Avastin administration.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMina Hosseini

Tabriz University of Medical Sciences

Ehsasatme2000@yahoo.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026